GS1-144 tablet

DRUG2 trials

Sponsors

Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions

Healthy VolunteerHepatic Impairment and Healthy FemaleVasomotor System; Labile

Phase 1

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population

CompletedNCT06385158

Changchun GeneScience Pharmaceutical Co., Ltd.Healthy Volunteer, Vasomotor System; Labile

Start: 2024-01-03End: 2024-11-05Updated: 2025-05-08

GS1-144 in Participants With Hepatic Impairment and Healthy Female

Not yet recruitingNCT07491289

Changchun GeneScience Pharmaceutical Co., Ltd.Hepatic Impairment and Healthy Female

Start: 2026-04-20End: 2027-06-30Target: 24Updated: 2026-03-24

Related Papers

Safety, Pharmacokinetics, and Pharmacodynamics of GS1-144, a Neurokinin-3 Receptor Antagonist: A Randomized Phase 1 Single and Multiple Ascending Dose and Food Effect Study.

2026-01-13